Publications by authors named "Andrew J Greenspan"
Article Synopsis
- The Psoriasis Longitudinal Assessment and Registry (PSOLAR) was established in 2007 as the first registry specifically for psoriasis patients, involving over 12,000 participants to assess long-term safety of biologic treatments.
- This study aimed to highlight the methodological limitations in safety evaluations within registries, focusing on a potential risk of major adverse cardiovascular events (MACE) associated with the drug ustekinumab.
- After refining analysis methods and addressing issues like patient imbalances and data limitations, the findings concluded no significant increase in MACE risk due to ustekinumab, emphasizing the importance of improving analytical techniques in observational studies.
Histamine is one of the best-characterized pruritogens in humans. It is known to play a role in pruritus associated with urticaria as well as ocular and nasal allergic reactions. Histamine mediates its effect via four receptors.
View Article and Find Full Text PDFThe histamine H4 receptor (H4R) is a promising target for the treatment of pruritus. A clinical study was conducted to evaluate the safety and efficacy of the H4R antagonist, JNJ 39758979 [(R)-4-(3-amino-pyrrolidin-1-yl)-6-isopropyl-pyrimidin-2-ylamine], on histamine-induced pruritus in healthy subjects. A single oral dose of 600 mg JNJ 39758979, 10 mg cetirizine, or placebo was administered in a randomized, three-period, double-blind, crossover study.
View Article and Find Full Text PDFThe histamine H4 receptor (H(4)R) has been shown to have preclinical involvement in both inflammatory and pruritic responses. JNJ-39758979 [(R)-4-(3-amino-pyrrolidin-1-yl)-6-isopropyl-pyrimidin-2-ylamine] is a potent and selective H(4)R antagonist with a Ki at the human receptor of 12.5 ± 2.
View Article and Find Full Text PDFBackground: Behavioural and psychological symptoms of dementia (BPSD) cannot be regarded as a single clinical syndrome, but rather as a heterogeneous group of symptoms, each of which can be considered as possible targets for therapy.
Objective: To compare the efficacy of risperidone and haloperidol on specific manifestations of BPSD.
Methods: A post-hoc analysis was conducted using data from an 18-week, randomized, double-blind, crossover head-to-head trial of risperidone vs haloperidol in treating 114 nursing-home residents with BPSD.
Objective: This study compared the effects of atypical antipsychotics (risperidone or quetiapine) with placebo and with each other in recently exacerbated patients with schizophrenia requiring hospitalization.
Methods: This international, randomized, double-blind study included a 2-week monotherapy phase followed by a 4-week additive therapy phase. Recently exacerbated patients with schizophrenia or schizoaffective disorder (DSM-IV) were randomized (2:2:1) to risperidone (n = 153), quetiapine (n = 156), or placebo (n = 73).
Background: Older individuals with dementia are highly sensitive to the effects of muscarinic receptor blockade.
Study Design: This was a 6-week multisite, randomized clinical trial.
Subjects: Eighty-six patients with probable Alzheimer's disease, vascular dementia, or mixed-etiology dementia (DSM-IV criteria) were randomly assigned to treatment with olanzapine or risperidone.